Loading
A phase 2 trial of Cemiplimab, Fianlimab in non-small-cell lung cancer and small-cell lung cancer, run by Regeneron Pharmaceuticals, active and no longer recruiting.
Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients is a phase 2 interventional study registered as NCT03916627 by Regeneron Pharmaceuticals, with 65 participants enrolled, started 2019-07-23 and due to reach its primary completion in 2025-03-31. Interventions recorded: cemiplimab, Platinum Doublet, fianlimab. Conditions listed: Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
Shares Fianlimab, Regeneron, Cemiplimab, Resectable stage I to III non-small-cell lung cancer.
Shares Fianlimab, Regeneron, Cemiplimab, Small-cell lung cancer.
Shares Fianlimab, Regeneron, Cemiplimab, Head and neck squamous cell carcinoma.
Shares Fianlimab, Regeneron, Cemiplimab, Small-cell lung cancer.
Shares Regeneron, Cemiplimab, Resectable stage I to III non-small-cell lung cancer, Small-cell lung cancer.
Shares Fianlimab, Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Fianlimab, Regeneron, Cemiplimab, Immune checkpoint inhibitors.